ResourcesVendorsMRISoftwarePolarean2500 Meridian Parkway #175 Durham, NC 27713 United StateseMail:Website:https://polarean.com/Latest from PolareanImaging LeadersPolarean appoints new chief medical advisorBy AuntMinnie.com staff writersPolarean Imaging has appointed Chase Hall, MD, as its new chief medical advisor.August 29, 2024MRIPolarean closes on $12.6M funding roundBy AuntMinnie.com staff writersPolarean Imaging has closed a $12.6 million financing round through the Alternative Investment Market of the London Stock Exchange.June 20, 2024Thoracic ImagingPolarean touts recent xenon MRI researchBy AuntMinnie.com staff writersPolarean is highlighting its recent research as a featured company and poster presenter at the ATS 2024 Respiratory Innovation Summit.May 8, 2024MRIPhilips inks xenon MRI contrast deal with PolareanBy AuntMinnie.com staff writersPhilips has partnered with MRI contrast agent developer Polarean to facilitate xenon-based lung ventilation imaging for routine clinical applications on the vendor's 7700 3-tesla MR scanner.June 1, 2023MRIPolarean touts first Xenoview patient scanBy AuntMinnie.com staff writersPolarean is touting the first patient scanned with the company's Xenoview technology, which took place at Cincinnati Children's Hospital Medical Center in Ohio.May 15, 2023MRIFDA approves Polarean's XenoviewBy AuntMinnie.com staff writersThe U.S. Food and Drug Administration (FDA) has approved Polarean's Xenoview, a drug-device combination that uses xenon-129 gas with MRI to visualize and quantify regional lung function.January 3, 2023MRIPolarean seeks FDA nod for Xe-129-based lung MRIBy AuntMinnie.com staff writersPolarean Imaging has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for its drug-device combination that uses hyperpolarized xenon-129 (Xe-129) gas with MRI to visualize and quantify regional lung function.October 6, 2020MRIPolarean Imaging reports on phase III lung trialsBy AuntMinnie.com staff writersPolarean Imaging is touting the results of two phase III clinical trials for its drug-device combination that uses hyperpolarized xenon-129 (Xe-129) gas with MRI to visualize and quantify regional lung function.January 29, 2020
